**PATENT** 

Attorney Docket No.: 28594/38247

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Shannon et al.	) "EXPRESS MAIL" mailing label No.
	) EU 424 299 470 US
Serial No.: 10/049,953	)
	) Date of Deposit: 18 June 2002
Filed: February 19, 2002	
	I hereby certify that this paper (or fee)
For: Recombinant Subunit Vaccine	is being deposited with the United
	States Postal Service "EXPRESS
Group Art Unit: To be assigned	MAIL POST OFFICE TO
	ADDRESSEE" service under 37 C.F.R.
Examiner: To be assigned	§1.10 on the date indicated above and
	is addressed to the Commissioner for
	Patents Box PCT, Washington, DC
	20231
	Kichaul Lin
,	Richard Zimmermann
<b>\</b>	Monard Ziminamian

## INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. §§ 1.56, 1.97, AND 1.98

Commissioner for Patents Box PCT Washington, D.C. 20231

Sic:

In compliance with 37 C.F.R. §1.97 and the continuing duty of disclosure under 37 C.F.R. §1.56, the applicants call to the attention of the examiner the enclosed publications, as listed on the attached Form PTO/SB/08A, which may be considered material to the examination of the above-identified patent application.

This information disclosure statement is not intended to be an admission that a search has been made, that other relevant art does not exist, or that any of the information disclosed herein constitutes prior art under 35 U.S.C. §102 or 35 U.S.C. §103.

This information disclosure statement is submitted before receipt of a first official action on the merits and consequently should be considered by the Patent Office without payment of a fee [see 37 C.F.R. §1.97(b)]. However, should the Patent Office determine that a fee is due for consideration of this information disclosure statement and accompanying publications, the Patent Office is hereby authorized to charge said fee to Deposit Account No. 13-2855.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN

Zm A. Carry A.

6300 Sears Tower

233 South Wacker Drive

Chicago, Illinois 60606-6402

(312) 474-6300

By:

Thomas A. Cawley, Jr., Ph.D.

Reg. No.: 40,994

June 18, 2002



PTO/SB/08A (10-01)
Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

The state of the s		Complete if Known			
Substitute for form 1449A/PTO				Application Number	10/049,953
INFORMATION DISCLOSURE				Filing Date	February 19, 2002
STATEMENT BY APPLICANT				First Named Inventor	Shannon et al.
			1 210/ (11)	Art Unit	To be assigned
(use as many sheets as necessary)		Examiner Name	To be assigned		
Sheet	1	of	2	Attorney Docket Number	28594/38247

Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	A1	5,591,632	01/07/1997	O'Donnell et al.
	A2	5,614,381	03/25/1997	Bromley et al.
	A3	5,736,146	04/07/1998	Cohen et al.
	A4	5,747,332	05/05/1998	Wallen et al.
	A5	5,776,465	07/07/1998	O'Donnell et al.
	A6	5,789,245	08/04/1998	Dubensky Jr. et al.
	A7	5,830,464	11/03/1998	Srivastava
	A8	5.837,251	11/17/1998	Srivastava

Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	
Initials*	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	
	B1 3	WO 95/24923	09/21/1995	Mount Sinai School of Medicine of the City University	
	-			of New York	
	B2	WO 96/37616	11/28/1996	The University of North Carolina at Chapel Hill et al.	
	B3	WO 97/06685	02/27/1997	Sloan-Kettering Institute for Cancer Research	
	B4	WO 97/06821	02/27/1997	Sloan-Kettering Institute for Cancer Research	
	B5	WO 97/06828	02/27/1997	Sloan-Kettering Institute for Cancer Research	
	B6	WO 97/10000	03/20/1997	Fordham University	
	B7	WO 97/10001	03/20/1997	Fordham University	
	B8	WO 97/10002	03/20/1997	Fordham University	
	B9	WO 98/12208	03/26/1998	The University of New Mexico	
	B10	WO 98/34641	08/13/1998	Fordham University	
	B11	WO 98/34642	08/13/1998	Fordham University	
	B12	WO 98/35705	08/20/1998	Whitehead Institute for Biomedical Research	
	B13	WO 99/02670	01/21/1999	The Government of the United States as represented	
	10.0	110 00/02010		by The Secretary of the Department of Health and	
	1			Human Services	
	B14	WO 99/07860	02/18/1999	Stressgen Biotechnologies Corporation	
	B15	WO 99/24049	05/20/1999	Protein Sciences Corporation	
	B16	WO 00/10597	03/02/2000	Immunobiology Limited	

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	Barrios et al., "Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Clamette Guerin priming," Eur. J. Immunol., 22(6):1365-72 (1992) (abstract only).	
	C2	Blachere et al., "Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity," J. Exp. Med., 186(8):1315-22	
	C3	Bruschke et al., "An experimental multivalent bovine virus diarrhea virus E2 subunit vaccine and two experimental conventionally inactivated vaccines induce partial fetal protection in sheep," Vaccine, 17(15-16):1983-91 (1999) (abstract only).	

Examiner	Date
Signature	Considered
Signature	



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

		Complete if Known			
Substitute for form 1449A/PTO				Application Number	10/049,953
INFORMATION DISCLOSURE				Filing Date	February 19, 2002
STATEMENT BY APPLICANT				First Named Inventor	Shannon et al.
31	(use as many sheets as necessary)			Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	2	285	2	Attorney Docket Number	28594/38247

C4	Lussow et al., "Mycobacterial heat-shock proteins as carrier molecules," Eur. J. Immunol.,
Ĭ	21(10):2297-302 (1991) (abstract only).
C5	Perraut et al., "Successful primate immunization with peptides conjugated to purified protein
	derivative or mycobacterial heat shock proteins in the absence of adjuvants," Clin. Exp.
	Immunol 93/3):382-6 (1993) (abstract only).
C6	Przepiorka & Srivastava, "Heat shock protein-peptide complexes as immunotnerapy for numari
	oppor " Mol. Med. Today, 4(11):478-84 (1998) (abstract only).
C7	Robert et al. "Phylogenetic conservation of the molecular and immunological properties of the
10,	changrapes gn96 and hsn70 " Fur .1 [mmuno]., 31:186-95 (2001).
C8	Srivastava & Udono, "Heat shock protein-peptide complexes in cancer immunotherapy," Curr.
100	On Immunol 6:728-32 (1994)
C9	Srivastava et al., "Heat shock proteins come of age: primitive functions acquire new roles in an
Ca	adoptive world," Immunity, 8:657-65 (1998).
	Srivastava, "Purification of heat shock protein-peptide complexes for use in vaccination
C10	against cancers and intracellular pathogens," Methods, 12(2):165-71 (1997) (abstract only).

Examiner	Date
	Considered
Signature	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.